.
Haematology
Study Course Description
Course Description Statuss:Approved
Course Description Version:9.00
Study Course Accepted:31.01.2024 08:42:08
Study Course Information | |||||||||
Course Code: | ISK_061 | LQF level: | Level 7 | ||||||
Credit Points: | 1.00 | ECTS: | 1.50 | ||||||
Branch of Science: | Clinical Medicine; Internal Medicine | Target Audience: | Medicine | ||||||
Study Course Supervisor | |||||||||
Course Supervisor: | Sandra Lejniece | ||||||||
Study Course Implementer | |||||||||
Structural Unit: | Department of Internal Diseases | ||||||||
The Head of Structural Unit: | |||||||||
Contacts: | Riga, 2 Hipokrata Street, iskrsu[pnkts]lv, +371 67042338 | ||||||||
Study Course Planning | |||||||||
Full-Time - Semester No.1 | |||||||||
Lectures (count) | 1 | Lecture Length (academic hours) | 1 | Total Contact Hours of Lectures | 1 | ||||
Classes (count) | 5 | Class Length (academic hours) | 3 | Total Contact Hours of Classes | 15 | ||||
Total Contact Hours | 16 | ||||||||
Study course description | |||||||||
Preliminary Knowledge: | 1. Hematopoiesis, blood cell division and maturation. 2. Pathological physiology and pathological anatomy of hematological diseases. 3. Changes in blood analysis. | ||||||||
Objective: | To promote the acquisition of knowledge about hematological diseases, their pathogenesis, clinical manifestations. To promote awareness of laboratory tests, in addition to examination methods used in cases of haematological diseases. To master the principles of differential diagnosis and treatment of hematological diseases. | ||||||||
Topic Layout (Full-Time) | |||||||||
No. | Topic | Type of Implementation | Number | Venue | |||||
1 | Acute leukemia. Myelodisplastic syndrome. Aplastic anemia. Definition, causes, pathogenesis, clinical manifestations, signs, changes in blood and bone marrow analysis, additional analyses, diagnosis approval and diferentialdiagnosis, complications, treatment principles (chemotherapy, bone marrow/peripheral stem cells transplantation, supportive treatment), prognosis of those diseases. Neutropenia. | Classes | 1.00 | clinical base | |||||
2 | Chronic lymphocytic leukemia, definition, causes, pathogenesis, symptoms and signs, changes in blood and bone marrow analyses, other investigations, complications, staging systems (Rai, Binet), diferencialdiagnosis, treatment, prognosis. Concept of chronic prolymphocytic leukemia, hairy cell leukemia. Hemolytic anemias – definition, causes, clasification, concept of clinical and laboratory diagnostic. Autoimmune hemolytic anemia. Hereditary hemolytic anemia. | Classes | 1.00 | clinical base | |||||
3 | Multiple myeloma – definition, pathogenesis, simptoms and singns, changes in blood and bone marrow analyses, diagnostic of M-gradient, staging, diferentialdiagnosis, complications, treatment, prognosis. Concept of solitary plasmacytoma, Waldenstrom disease. Monoclonal gammopathy of undetermined significance. | Classes | 1.00 | clinical base | |||||
4 | Lymphoma: Hodgkin's disease, non Hodgkin's lymphoma – definition, causes, pathogenesis, symptoms and signs, staging, changes in analyses, additionally analyses (histology, CT, PET), diferencialdiagnosis, treatment, prognosis. | Classes | 1.00 | clinical base | |||||
5 | Chronic myeloproliferative leukemias: chronic myelogeneus leukemia (CML), polycythemia vera, myelofibrosis, essential thrombocythemia – definition, changes in blood and bone marrow analyses, additional investigations, staging, diferentialdiagnosis, treatment, prognosis. Secundary erythrocytosis and trombocytosis, causes. | Classes | 1.00 | clinical base | |||||
6 | Diagnostic principles in cause of hematological diseases. | Lectures | 1.00 | E-Studies platform | |||||
Assessment | |||||||||
Unaided Work: | 1. Individual work with the patient – collection of anamnesis, examination interpretation, treatment planning, formulation of a possible diagnosis. 2. Obtaining additional information about a particular subject. In order to evaluate the quality of the study course as a whole, the student must fill out the study course evaluation questionnaire on the Student Portal. | ||||||||
Assessment Criteria: | 1. Tests during the lessons. 2. Situation tasks during the lessons. 3. Written test (test questions, at least 55% of correct answers). | ||||||||
Final Examination (Full-Time): | Exam | ||||||||
Final Examination (Part-Time): | |||||||||
Learning Outcomes | |||||||||
Knowledge: | 1. As a result of mastering the study course students will be able to formulate differential diagnoses. 2. Will be able to assess the patient's condition and draw up a treatment plan. 3. Name and describe the most common haematological diseases. | ||||||||
Skills: | On successful completion of the course, students will be able to recognise and make a laboratory or other examination plan, classify and confirm the diagnosis, plan patient's treatment, explain the prognosis in cases of acute leukemia, myelodysplastic syndromes, aplastic anemia, chronic lymphocytic leukemia, multiple myeloma, Hodgkin's disease, Waldenström’s disease, plazmacitoma, non-Hodgkin's lymphomas, chronic myeloid leukemia, polycythemia vera, myelofibrosis, essential thrombocythemia and will be able to formulate a differential diagnosis in cases of haematological diseases. | ||||||||
Competencies: | On successful completion of the course, students will be able to develop an investigation plan for haematological diseases, explain laboratory and other additional examination results, differentiate the changes and identify the most common haematological diseases. | ||||||||
Bibliography | |||||||||
No. | Reference | ||||||||
Required Reading | |||||||||
1 | S.Lejniece. Klīniskā hematoloģija. Nacionālais Medicīnas Apgāds, 2020. | ||||||||
2 | Klīniskā medicīna prof. A.Lejnieka redakcijā. Medicīnas Apgāds, 785-914, 2010 (akceptējams izdevums) | ||||||||
3 | Conn's Current Therapy. 2022. Kellerman, Rick D; Rakel, David P. by Elsevier Inc | ||||||||
4 | The Merck Manual of diagnosis and therapy. . 20th Edition, Centennial Edition, 2018. | ||||||||
5 | Hoffbrand's Essential Haematology. 8th ed. A.V.Hoffbrand, P.A.H.Moss. Wiley-Blackwell, 2020. | ||||||||
6 | Ārvalstu studentiem/For international students: | ||||||||
7 | Conn's Current Therapy, 2020. Kellerman, Rick D.; Rakel, David P. by Elsevier Inc | ||||||||
8 | The Merck Manual of diagnosis and therapy. 20th Edition, Centennial Edition, 2018. | ||||||||
9 | Hoffbrand's Essential Haematology. 8th Edition. A.V.Hoffbrand, P.A.H.Moss. Wiley-Blackwell, 2020 | ||||||||
Additional Reading | |||||||||
1 | Blood Cells: A Practical Guide. by Barbara J. Bain, 5th Edition. Wiley Blackwell, 2015. | ||||||||
2 | A.Rivkina. Plūsmas citometrijas metode hematoloģisko slimību diagnostikā. 2019. SIA “Medicīnas apgāds”, 72-89. | ||||||||
3 | Klīnisko analīžu rokasgrāmata. E.Gulbja laboratorija. Izdevējs E.Gulbja laboratorija, 2018. | ||||||||
4 | Dacie and Lewis Practical Haematology. E-Book 12th Edition, Kindle Edition by Barbara J. Bain, Imelda Bates, Mike A Laffan, 2017. | ||||||||
5 | M. Heuser, Y. Ofran, et.al. on behalf of the ESMO Guidelines Committee. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2020); 31(0): 697-712. | ||||||||
6 | Swerdlow S.H. et al The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127 (20):2375-2390. | ||||||||
7 | Haematology: A Core Curriculum. 1st Edition by Barbara Jane Bain, 2020 | ||||||||
8 | D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. M. Ribera, C. Buske on behalf of the ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27 (Supplement 5): v69–v82. | ||||||||
9 | E Kastritis, V Leblond, et.al. ESMO Guidelines Committee. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.. Annals of Oncology, 2018, Vol 29, (Supplement 4): iv41–iv50 | ||||||||
10 | NCCN clinical Practice Guidelins in Oncology. Myeloproliferative Neoplasms. Version 2.2018. | ||||||||
11 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published in 2021 – Ann Oncol (2021) Authors: M.A. Dimopoulos, P. Moreau, E. Terpos, M. V. Mateos, S. Zweegman, G. Cook, M. Delforge, R. Hájek, F. Schjesvold, M. Cavo, H. Goldschmidt, T. Facon, H. Einsele, M. Boccadoro, J. San-Miguel, P. Sonneveld & U. Mey on behalf of the EHA Guidelines Committee and ESMO Guidelines https://www.esmo.org/guidelines/guidelines-by-topic/haemato… | ||||||||
12 | Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405. | ||||||||
13 | Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Published in 2020 – Ann Oncol (2020) Authors: B. Eichhorst, T. Robak, E. Montserrat, P. Ghia, C. U. Niemann, A. P. Kater, M. Gregor, F. Cymbalista, C. Buske, P. Hillmen, M. Hallek & U. Mey, on behalf of the ESMO Guidelines Committeehttps://www.esmo.org/guidelines/guidelines-by-topic/haemato… | ||||||||
14 | A. Hochhaus, S. Saussele, G. Rosti, F.-X. Mahon, J.J.W.M. Janssen, H. Hjorth-Hansen, J. Richter, C. Buske. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Volume 28, Supplement 4, 2017, Pages iv41-iv51, ISSN 0923-7534,https://doi.org/10.1093/annonc/mdx219. (https://www.sciencedirect.com/science/article/pii/S09237534…) | ||||||||
15 | Pocket Oncology (Pocket Notebook) (Kindle Edition) by Alexander Drilon, Michael Postow, 2019. | ||||||||
16 | Global Hematolog.y by David J Roberts; D J Weatherall. Elservier, 2016. | ||||||||
17 | Guinan EC. Diagnosis and managment of aplastic anemia. Hematology Am Soc Hematol Educ program 2011; 2011:76. | ||||||||
18 | Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012; 2012:292. | ||||||||
19 | Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672. | ||||||||
20 | Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Published in 2020 – Ann Oncol (2020) Authors: P. Fenaux, D. Haase, V. Santini, G.F. Sanz, U. Platzbecker & U. Mey, on behalf of the ESMO Guidelines Committeehttps://www.esmo.org/guidelines/guidelines-by-topic/haemato… | ||||||||
21 | Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26:2172–2175. | ||||||||
22 | A.Hochhaus, M. Baccarani, et al. European LeukemiaNet 2020 recommendations for treatment chronic myeloid leukemia. Leukemia, 2020, 34: 966-984. | ||||||||
23 | Eichenauer DA, Aleman BMP, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 (Supplement 4): iv19–iv29. | ||||||||
24 | Postgraduate Haematology by A. Victor Hoffbrand and Douglas R. Higgs, 2016. | ||||||||
25 | Ārvalstu studentiem/For international students: | ||||||||
26 | Dacie and Lewis Practical Haematology. E-Book 12th Edition, Kindle Edition by Barbara J. Bain, Imelda Bates, Mike A Laffan, 2017. | ||||||||
27 | Blood Cells: A Practical Guide. by Barbara J. Bain, 5th Edition. Wiley Blackwell, 2015. | ||||||||
28 | NCCN clinical Practice Guidelins in Oncology. Myeloproliferative Neoplasms. Version 2.2018. | ||||||||
29 | Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672. | ||||||||
Other Information Sources | |||||||||
1 | ASH mājas lapa (http://www.hematology.org/) | ||||||||
2 | EHA mājas lapa (http://www.ehaweb.org/) |